Bringing microbiome-drug interaction research into the clinic

Leah Guthrie, Libusha Kelly

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Our understanding of the scope and clinical relevance of gut microbiota metabolism of drugs is limited to relatively few biotransformations targeting a subset of therapeutics. Translating microbiome research into the clinic requires, in part, a mechanistic and predictive understanding of microbiome-drug interactions. This review provides an overview of microbiota chemistry that shapes drug efficacy and toxicity. We discuss experimental and computational approaches that attempt to bridge the gap between basic and clinical microbiome research. We highlight the current landscape of preclinical research focused on identifying microbiome-based biomarkers of patient drug response and we describe clinical trials investigating approaches to modulate the microbiome with the goal of improving drug efficacy and safety. We discuss approaches to aggregate clinical and experimental microbiome features into predictive models and review open questions and future directions toward utilizing the gut microbiome to improve drug safety and efficacy.

Original languageEnglish (US)
JournalEBioMedicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug interactions
Microbiota
Drug Interactions
Research
Pharmaceutical Preparations
Pharmacological Biomarkers
Metabolism
Toxicity
Safety
Biotransformation
Drug-Related Side Effects and Adverse Reactions
Clinical Trials

Keywords

  • Drug metabolism
  • High throughput genomics
  • Metabolomics
  • Microbiome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bringing microbiome-drug interaction research into the clinic. / Guthrie, Leah; Kelly, Libusha.

In: EBioMedicine, 01.01.2019.

Research output: Contribution to journalReview article

@article{0df48b389225497a9c12b083d72c108a,
title = "Bringing microbiome-drug interaction research into the clinic",
abstract = "Our understanding of the scope and clinical relevance of gut microbiota metabolism of drugs is limited to relatively few biotransformations targeting a subset of therapeutics. Translating microbiome research into the clinic requires, in part, a mechanistic and predictive understanding of microbiome-drug interactions. This review provides an overview of microbiota chemistry that shapes drug efficacy and toxicity. We discuss experimental and computational approaches that attempt to bridge the gap between basic and clinical microbiome research. We highlight the current landscape of preclinical research focused on identifying microbiome-based biomarkers of patient drug response and we describe clinical trials investigating approaches to modulate the microbiome with the goal of improving drug efficacy and safety. We discuss approaches to aggregate clinical and experimental microbiome features into predictive models and review open questions and future directions toward utilizing the gut microbiome to improve drug safety and efficacy.",
keywords = "Drug metabolism, High throughput genomics, Metabolomics, Microbiome",
author = "Leah Guthrie and Libusha Kelly",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ebiom.2019.05.009",
language = "English (US)",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Bringing microbiome-drug interaction research into the clinic

AU - Guthrie, Leah

AU - Kelly, Libusha

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Our understanding of the scope and clinical relevance of gut microbiota metabolism of drugs is limited to relatively few biotransformations targeting a subset of therapeutics. Translating microbiome research into the clinic requires, in part, a mechanistic and predictive understanding of microbiome-drug interactions. This review provides an overview of microbiota chemistry that shapes drug efficacy and toxicity. We discuss experimental and computational approaches that attempt to bridge the gap between basic and clinical microbiome research. We highlight the current landscape of preclinical research focused on identifying microbiome-based biomarkers of patient drug response and we describe clinical trials investigating approaches to modulate the microbiome with the goal of improving drug efficacy and safety. We discuss approaches to aggregate clinical and experimental microbiome features into predictive models and review open questions and future directions toward utilizing the gut microbiome to improve drug safety and efficacy.

AB - Our understanding of the scope and clinical relevance of gut microbiota metabolism of drugs is limited to relatively few biotransformations targeting a subset of therapeutics. Translating microbiome research into the clinic requires, in part, a mechanistic and predictive understanding of microbiome-drug interactions. This review provides an overview of microbiota chemistry that shapes drug efficacy and toxicity. We discuss experimental and computational approaches that attempt to bridge the gap between basic and clinical microbiome research. We highlight the current landscape of preclinical research focused on identifying microbiome-based biomarkers of patient drug response and we describe clinical trials investigating approaches to modulate the microbiome with the goal of improving drug efficacy and safety. We discuss approaches to aggregate clinical and experimental microbiome features into predictive models and review open questions and future directions toward utilizing the gut microbiome to improve drug safety and efficacy.

KW - Drug metabolism

KW - High throughput genomics

KW - Metabolomics

KW - Microbiome

UR - http://www.scopus.com/inward/record.url?scp=85066123242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066123242&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2019.05.009

DO - 10.1016/j.ebiom.2019.05.009

M3 - Review article

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -